Loading...
By Amy Orciari Herman
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
The chemical N-nitrosodiethylamine (NDEA) has been detected in three lots of valsartan from Torrent Pharmaceuticals, the FDA announced late last week. NDEA is a known carcinogen in animals and a suspected carcinogen in humans.
The three lots were part of the company's August recall of valsartan over N-nitrosodimethylamine (NDMA), a probable carcinogen. The FDA notes that both impurities result from "a specific sequence of manufacturing steps and chemical reactions."
The agency says it will continue to test valsartan products for NDEA and other impurities, and will ensure that any affected products are recalled. The FDA will update its list of recalled products accordingly (see second link below).
Comment
LINK(S):
FDA news release (Free)
FDA list of recalled valsartan products (Free PDF)
Background: Physician's First Watch coverage of NDMA-contaminated valsartan & cancer risk (Free)